Download Products - Hampshire LPC website

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
Transcript
Products Miscellany and Supply Problems March/April 2016
Products
Product Information
Supply Now Available
New product:
This new strength has been added to the
BuTrans®
range of topical buprenorphine products
(buprenorphine)
available. It is licensed for use in adults with
15
non-malignant pain of moderate intensity
microgram/hour
when an opioid is necessary for obtaining
transdermal
adequate analgesia.
patch
Comments
Dovobet® Gel
Applicator
Dovobet gel should be applied to the
affected area once daily. The
recommended treatment time is 4
weeks for scalp psoriasis and 8
weeks for mild to moderate nonscalp psoriasis.
Dovobet® Gel Applicator
(calcipotriol/betamethasone 60gdipropionate) is now available –as a new
addition to the Dovobet® family.
The company recommends the Applicator for
“targeted and no touch application “areas of
psoriasis, as the Applicator facilitates precise
application, delivering 0.05g with every
squeeze.
Information for Community Pharmacists
For Community
Summary of recent distribution changes can
Pharmacists if
be accessed via the PSNC website or via
unable to source this link:
certain products
Link to manufacturers contingency plans
Cilique® oral
contraceptive
Cilique® (norgestimate
250mcg/ethinyllestradiol 35mcg) has been
recently launched by Consilient Health.
General Information
Fusidic acid 1%
Fucithalmic® eye drops have been
eye drops
discontinued by AMCo, but they are now
making a generic fusidic acid 1%
modified-release (MR) eye drops product
instead.
The cost of the eye drops has consequently
increased from approx. £2.60 for
Fucithalmic® eye drops 5g, to £29.06 for
generic fusidic acid 1% MR eye drops 5g.
Please be aware that chloramphenicol 0.5%
eye drops are recommended as the first-line
treatment for acute bacterial conjunctivitis in
the majority of patients, where antibiotic
treatment is required.
Fusidic acid 1% MR eye drops should not be
routinely used first line due to high cost and
increased incidence of adverse effects.
Locally, GPs are recommended to
prescribe the Consilient health range
of oral contraceptives as these are
one of the most cost effective range
currently.
Key Messages:
If a topical ocular antibiotic is
considered necessary, local
Antimicrobial Guidelines recommend
chloramphenicol 0.5% eye drops
first-line.
Fusidic acid 1% MR eye drops (5g)
should be reserved as a treatment
option for patients who:



are pregnant or breastfeeding
have a personal or family
history of blood dyscrasias
(such as aplastic anaemia)
are intolerant of
chloramphenicol
may require assistance in applying
drops, e.g. young children or elderly
people (fusidic acid requires twice
daily administration.
Tin Orchel Medicines Management Team Southampton City CCG
D:\840969513.doc
E-mail [email protected]
Products Miscellany and Supply Problems March/April 2016
NHS stationery
ordering portal
Primary Care Support England (PCSE)’s
online portal for ordering NHS stationery has
gone live, and all community pharmacy
contractors should have received registration
letters. If any queries arise, the PCSE
website has a number of helpful FAQs:
HELP
Revised SPC:
Natrilix SR®
(indapamide)
Myopia, blurred vision and visual impairment
have been added as potential adverse effects
to treatment.
Revised SPC:
Aldactone®
tablets
(spironolactone)
– all strengths
Sections 4.4, 4.5 and 4.8 have been updated
to include information on the risk of severe
hyperkalaemia, information on the
concomitant use of
trimethoprim/sulfamethoxazole with
spironolactone, and the adverse reaction
pemphigoid.
Section 4.4 now includes a paragraph on the
laboratory monitoring of testosterone level to
ensure maintenance of eugonadal
testosterone levels and a warning on use of
testosterone in men with hypertension.
Revised SPC:
Nebido®
(testosterone)
1000mg/4ml,
solution for
injection
Revised SPCs:
Madopar®
(levodopa/benser
aside) products
Revised SPC:
Requip® 0.25
mg (ropinirole
hydrochloride)
Tablets
Zika virus:
updated travel
advice for
pregnant women
by Public Health
England (PHE)
Zika virus
infection:
guidance for
primary care
www.medicines.org.uk
For more information visit:
www.medicines.org.uk
For more information visit:
www.medicines.org.uk
SPC has been revised to warn that urine test
results may give a false positive for ketone
bodies.
For more information visit:
Peripheral oedema is now listed as an
undesirable effect of ropinirole tablets.
For more information visit:
www.medicines.org.uk
www.medicines.org.uk
PHE and the National Travel Health Network
and Centre (NaTHNaC) recommend that
pregnant women should postpone nonessential travel to areas with active Zika
transmission until after pregnancy. This is a
change to the previous advice which
encouraged pregnant women to avoid travel
PHE has issued updated guidance clarifying
advice on preventing sexual transmission to
pregnant women and women planning
pregnancy and advice for
immunocompromised patients, and Guillain
Barre syndrome, and a new section on
performing minor procedures in the primary
care setting.
Tin Orchel Medicines Management Team Southampton City CCG
D:\840969513.doc
One query that has been raised a
number of times is “Will I be charged
for my order?” This question has
arisen because the online ordering
portal includes prices for many of
the items. As stated in the relevant
FAQ, contractors will not be charged
for standard orders made using the
portal. PCSE is committed to
ensuring NHS England supplies are
ordered responsibly and for this
reason, prices for items are included
to help contractors make an
informed decision about what they
need. (Note, there may be a charge
for urgent supplies.)
For more information visit:
For more information:
Zika virus updated
travel advice for pregnant women - News stories - GOV_UK.mht
For more information visit:
Zika_virus_guidance
_for_primary_care_01_March_2016_v3.0.pdf
E-mail [email protected]